AlcoChange: A digital therapeutic for patients with alcohol-related liver disease.

ABSTRACT:

Background & aims

Maintenance of abstinence in alcohol-related liver disease (ARLD) is a major unmet therapeutic need. Digital therapeutics can deliver ongoing behavioural therapy, in real-time, for chronic conditions. The aim of this project was to develop and clinically test AlcoChange, a novel digital therapeutic for ARLD.

Methods

AlcoChange was developed using validated behaviour change techniques and a digital alcohol breathalyser. This was an open-label, single-centre study. Patients with ARLD, ongoing alcohol use (within 1 month) and possession of a suitable smartphone were eligible. Patients were recruited from inpatient and outpatient settings, and received AlcoChange therapy for 3 months. The primary outcome was reduction in alcohol use from baseline to 3 months, m

SUBMITTER: Mehta G 

PROVIDER: S-EPMC10899036 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature